NCT00192140已完成4 期
An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 345
- 试验地点
- 22
- 主要终点
- To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses.
研究概览
简要总结
- To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses.
- To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
- To describe the genotypic and phenotypic stability of shed vaccine viruses.
- To describe the immune responses of FluMist in individuals 5-49 years of age.
- To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response
详细描述
The purpose of this study is to evaluate the viral shedding, immunogenicity and safety of FluMist when administered to healthy individuals between 5-49 years of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 49 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •5-49 years of age;
- •In good health;
- •Individual or parent/guardian available by telephone;
- •Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol; and
- •Signed informed consent and HIPAA authorization by the participant or parent/guardian.
排除标准
- •History of hypersensitivity to any component of FluMist, including egg or egg products;
- •History of hypersensitivity to gentamicin;
- •Close contact who is immunocompromised within the same household;
- •Known or suspected immune deficiency diseases or immunosuppressed or have altered or compromised immune status as a consequence of treatment with immunosuppressive therapies;
- •History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies;
- •History of Guillain-Barré syndrome;
- •History of asthma or reactive airways disease;
- •Acute febrile (>100.0°F oral) and/or respiratory illness, within the 72 hours prior to enrollment;
- •For children and adolescents - use of aspirin or aspirin containing products in the month prior to enrollment or anticipated use during the study;
- •Pregnancy or, in biologically capable women (e.g., menses within the last year), not willing to agree to acceptable birth control for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
- •Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study;
- •Administration of any live virus vaccine within one month prior to enrollment or if receipt of another live virus vaccine is expected within one month of the vaccination in this study;
- •Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks of the vaccination in this study;
- •Participation in another investigational trial or administration of any investigational drug within one month prior to enrollment or during this study;
- •Employees of the research center, any individuals involved with the conduct of the study, or any family member of such individuals;
- •Laboratory confirmed influenza (positive culture or rapid antigen test) in the prior influenza season (2003/2004 or 2004/2005 season);
- •Receipt of any influenza vaccine in the prior influenza season; and
- •Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.
结局指标
主要结局
To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses.
时间窗: 28 days after vaccination
To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
时间窗: 28 days after vaccination
次要结局
- To describe the immune responses of FluMist in indivduals 5-49 years of age.(28 days after vaccination)
- To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response.(28 days after vaccination)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant RecipientsCovid19Kidney Transplant InfectionNCT04701528Leiden University Medical Center20
已完成
不适用
Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza PatientsInfluenzaNCT01839760Crucell Holland BV150
已完成
3 期
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic DermatitisAtopic DermatitisNCT04250350Eli Lilly and Company206
撤回
2 期
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.Renal ImpairmentEnd-stage Renal DiseaseNCT02397395Janssen R&D Ireland
已完成
4 期
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of AgeHealthyInfluenzaNCT03143101MedImmune LLC200